Scarica l'app Stockscreener
6.63
6.42%
0.40
Pre-mercato:
6.59
-0.04
-0.60%
Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie
Vanda Pharmaceuticals stock rises after FDA submission for GPP treatment - Investing.com
Vanda submits BLA to FDA for generalized pustular psoriasis drug - Investing.com
Vanda Pharmaceuticals (VNDA) Submits BLA to FDA for New Psoriasis Treatment - GuruFocus
Vanda Announces Submission Of Biologics License Application To The FDA For Imsidolimab For The Treatment Of Generalized Pustular Psoriasis - TradingView — Track All Markets
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - PR Newswire
Vanda Pharmaceuticals, The New York Islanders New Jersey Sponsor - Yahoo Sports Canada
Cantor Fitzgerald Maintains Vanda Pharmaceuticals (VNDA) Overweight Recommendation - MSN
Vanda Pharmaceuticals Says FDA Will Take More Time To Decide On Tradipitant Clinical Hold Re-Review - MSN
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference - The AI Journal
Vanda jumps as FDA lifts tradipitant partial clinical hold - MSN
FDA lifts partial clinical hold on Vanda Pharmaceuticals’ tradipitant - MSN
Vanda Pharmaceuticals Inc. $VNDA Holdings Cut by Schroder Investment Management Group - MarketBeat
Stonepine Capital Management LLC Has $1.18 Million Position in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
What insider trading reveals about Vanda Pharmaceuticals Inc. stockStop Loss & Real-Time Volume Surge Alerts - Newser
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness - The Malaysian Reserve
Vanda Pharmaceuticals (VNDA) Soars After FDA Lifts Tradipitant H - GuruFocus
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickne - GuruFocus
Vanda Says FDA Lifts Partial Hold on Tradipitant Motion-Sickness Study - marketscreener.com
FDA lifts partial clinical hold on Vanda’s tradipitant for motion sickness - Investing.com India
FDA Lifts Hold on Vanda’s Tradipitant Trials - TipRanks
FDA Lifts Hold on Vanda Pharmaceuticals' (VNDA) Tradipitant Stud - GuruFocus
Vanda Pharmaceuticals stock rises after FDA lifts partial clinical hold By Investing.com - Investing.com Canada
Will Vanda Pharmaceuticals Inc. (VM4) stock see insider accumulation2025 EndofYear Setup & High Conviction Trade Alerts - Newser
Vanda Pharmaceuticals (VNDA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Is Vanda Pharmaceuticals Inc. (VM4) stock attractive for growth fundsMarket Activity Report & Low Risk Growth Stock Ideas - Newser
Will Vanda Pharmaceuticals Inc. (VM4) stock benefit from mergersWeekly Stock Report & Weekly Setup with High ROI Potential - Newser
Can Vanda Pharmaceuticals Inc. (VM4) stock double in coming years2025 Risk Factors & Free Long-Term Investment Growth Plans - Newser
How Vanda Pharmaceuticals Inc. (VM4) stock reacts to new regulations2025 Volatility Report & Daily Oversold Bounce Ideas - Newser
How Vanda Pharmaceuticals Inc. (VM4) stock moves in volatile trading sessionsPortfolio Gains Summary & AI Optimized Trading Strategy Guides - Newser
How Vanda Pharmaceuticals Inc. (VM4) stock reacts to weak economy - Newser
How Vanda Pharmaceuticals Inc. (VM4) stock reacts to monetary easingProfit Target & Risk Controlled Stock Alerts - Newser
Will Vanda Pharmaceuticals Inc. stock pay special dividends - Newser
H.C. Wainwright reiterates Buy rating on Vanda Pharmaceuticals stock By Investing.com - Investing.com Canada
Vanda Pharmaceuticals (Nasdaq:VNDA) Provides Key Regulatory Update on Motion Sickness Therapy - Kalkine Media
Should You Invest in This Under-the-Radar Weight Loss Stock? - The Motley Fool
Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Lowered by Wall Street Zen - MarketBeat
FDA Extends Review of Vanda Pharmaceuticals' (VNDA) Tradipitant - GuruFocus
FDA re-review of Vanda tradipitant partial clinical hold extended - Seeking Alpha
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness - GuruFocus
Vanda Pharmaceuticals (VNDA) Updates on Tradipitant for Motion S - GuruFocus
Vanda Pharmaceuticals Updates on Tradipitant FDA Review - TipRanks
Vanda Pharmaceuticals provides regulatory update on Tradipitant for motion sickness - marketscreener.com
Vanda Pharmaceuticals Provides Regulatory Update On Tradipitant For Motion Sickness - TradingView
Vanda Pharmaceuticals Inc Provides Regulatory Update on Tradipitant - TradingView
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness – Company Announcement - Financial Times
Published on: 2025-11-28 08:55:55 - moha.gov.vn
Will Vanda Pharmaceuticals Inc. stock gain from government policiesJuly 2025 Sector Moves & Fast Gaining Stock Reports - BỘ NỘI VỤ
In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder (PR Newswire) - Aktiellt
Vanda Sees Sales Jump, But Losses Also Pile Up - Finimize
Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results (PR Newswire) - Aktiellt
Vanda a new buy at B. Riley on 'historic discount' - MSN
Will Vanda Pharmaceuticals Inc. (VM4) stock test record highs in 2025Wall Street Watch & Capital Efficient Trade Techniques - newser.com
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):